A Phase 3 interventional study of Vortioxetine in Depressive Disorder, Major, sponsored by Takeda. Completed. Open to participants aged 18 Years to 77 Years. Per ClinicalTrials.gov, last updated 2014-05-28.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 2nd largest by enrollment, is one of 6 that started in 2010, is one of 31 in phase 3, and was the 12th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 77 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,075 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
26 studies in Depressive Disorder, Major by Takeda: 1 open now, 1 under way, 1 of them phase 3. Of 25 finished, 24 (96%) have results posted.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 6th largest by enrollment of the 24 interventional ones that give a count, is one of 5 that started in 2010, is one of 16 in phase 3, and was the 7th registered.
Takeda’s Depressive Disorder, Major studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.
Depression has been recognized as a chronic illness that imposes a significant burden on individuals, families and society. Major depressive disorder (MDD) is among the most important causes of disability worldwide, in both developing and developed countries. Major depressive disorder is reported to be the most common mood disorder, with a lifetime prevalence of about 15% and as high as 25% in women. Major depressive disorder is characterized by the presence of 1 or more major depressive episodes that presents with depressed mood, loss of interest or pleasure, disturbed sleep or appetite, low energy, feelings of guilt or low self-worth, and poor concentration.
This is a multicenter extension study designed to allow eligible patients who have completed short-term efficacy and safety studies LuAA21004_315 (NCT01153009), LuAA21004_316 (NCT01163266) and LuAA21004_317 (NCT01179516) to receive the 52-week treatment with vortioxetine in this open-label extension study. Participants are expected to return to the site for approximately 13 visits.
A safety follow-up call will be made 4 weeks after completion of the 52-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks.
Drug: Vortioxetine
Vortioxetine tablets
Also known as: LuAA21004
Number of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of ≥5%
Treatment-emergent adverse events (TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.
Time frame: Over the 52 week period
Number of Participants With Serious Treatment-Emergent Adverse Events
Serious treatment-emergent adverse events (serious-TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A serious-TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing. Serious Adverse Events include adverse events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered serious adverse events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.
Time frame: Over the 52 week period
Treatment-Emergent Adverse Events Leading to Study Discontinuation
Treatment-emergent adverse events are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.
Time frame: Over the 52 week period
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
The change between MADRS total score at each assessed visit and MADRS score at baseline. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.
Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44, and 52
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
The change between HAM-A score at each assessed visit and HAM-A score at baseline. HAM-A is a 14 item rating scale to quantify anxiety symptomatology severity (i.e., anxious mood, tension, fear, insomnia, etc.) rated on a 5-point scale from 0 (not present) to 4 (severe) with a total score range from 0 to 56. Higher scores indicate greater severity of symptoms.
Time frame: Baseline and Weeks 4, 24, and 52
Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)
The change between CGI-S score at each assessed visit and CGI-S score at baseline. The CGI-S assesses the clinician's impression of the subject's current state of mental illness and consists of one question for the investigator: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on a seven-point scale (1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=extremely ill). Higher scores indicate greater severity of illness.
Time frame: Baseline and Weeks 4, 24, and 52
Change From Baseline in Sheehan Disability Scale (SDS) Total Score
The change between the SDS total score at each assessed visit and the total score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment.
Time frame: Baseline and Weeks 12, 24, 36, and 52
Change From Baseline in SDS Work/School Subscale
The change between the Sheehan Disability work/school subscale score at each assessed visit and work/school subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.
Time frame: Baseline and Weeks 12, 24, 36, and 52
Change From Baseline in SDS Social Life Subscale
The change between the Sheehan Disability social life subscale score at each assessed visit and social life subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.
Time frame: Baseline and Weeks 12, 24, 36, and 52
Change From Baseline in SDS Family Life/Home Responsibilities Subscale
The change between the Sheehan Disability family life/home responsibilities subscale score at each assessed visit and family life/home responsibilities subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.
Time frame: Baseline and Weeks 12, 24, 36, and 52
Participants took part in the study at 143 investigative sites in the United States from 07 Sep 2010 to 31 May 2013.
| Milestone | Vortioxetine |
|---|---|
| Started | 1075 |
| Treated | 1073 |
| Completed | 538 |
| Not completed | 537 |
| Withdrew: Withdrawal by subject | 142 |
| Withdrew: Adverse event | 115 |
| Withdrew: Lost to follow-up | 112 |
| Withdrew: Lack of efficacy | 68 |
| Withdrew: Noncompliance | 41 |
| Withdrew: Other | 36 |
| Withdrew: Protocol violation | 22 |
| Withdrew: Elevated liver enzymes | 1 |
Treatment-emergent adverse events (TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.
| participants | Vortioxetine |
|---|---|
| Nausea | 258 |
| Diarrhea | 80 |
| Vomiting | 68 |
| Constipation | 65 |
| Nasopharyngitis | 68 |
| Viral upper respiratory tract infection | 66 |
| Upper respiratory tract infection | 60 |
| Weight increased | 65 |
| Headache | 136 |
| Insomnia | 56 |
Serious treatment-emergent adverse events (serious-TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A serious-TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing. Serious Adverse Events include adverse events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered serious adverse events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.
| participants | Vortioxetine |
|---|---|
| Number of Participants With Serious Treatment-Emergent Adverse Events | 29 |
Treatment-emergent adverse events are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.
| participants | Vortioxetine |
|---|---|
| Treatment-Emergent Adverse Events Leading to Study Discontinuation | 117 |
The change between MADRS total score at each assessed visit and MADRS score at baseline. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.
| units on a scale | Vortioxetine |
|---|---|
| Week 1 (n=1043) | -2.7 ± 6.32 |
| Week 2 (n=1043) | -4.8 ± 7.50 |
| Week 4 (n=1004) | -6.1 ± 8.50 |
| Week 8 (n=936) | -7.9 ± 9.19 |
| Week 12 (n=843) | -8.5 ± 9.55 |
| Week 16 (n=777) | -9.1 ± 9.50 |
| Week 20 (n=747) | -9.4 ± 10.03 |
| Week 24 (n=697) | -9.7 ± 9.64 |
| Week 28 (n=670) | -9.5 ± 10.20 |
| Week 36 (n=617) | -9.7 ± 10.44 |
| Week 44 (n=573) | -10.3 ± 10.70 |
| Week 52 (n=534) | -10.3 ± 11.00 |
The change between HAM-A score at each assessed visit and HAM-A score at baseline. HAM-A is a 14 item rating scale to quantify anxiety symptomatology severity (i.e., anxious mood, tension, fear, insomnia, etc.) rated on a 5-point scale from 0 (not present) to 4 (severe) with a total score range from 0 to 56. Higher scores indicate greater severity of symptoms.
| units on a scale | Vortioxetine |
|---|---|
| Week 4 (n=1029) | -2.6 ± 4.98 |
| Week 24 (n=742) | -4.2 ± 5.84 |
| Week 52 (n=548) | -4.8 ± 6.52 |
The change between CGI-S score at each assessed visit and CGI-S score at baseline. The CGI-S assesses the clinician's impression of the subject's current state of mental illness and consists of one question for the investigator: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on a seven-point scale (1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=extremely ill). Higher scores indicate greater severity of illness.
| units on a scale | Vortioxetine |
|---|---|
| Week 4 (n=1030) | -0.6 ± 0.99 |
| Week 24 (n=743) | -1.0 ± 1.16 |
| Week 52 (n=549) | -1.2 ± 1.32 |
The change between the SDS total score at each assessed visit and the total score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment.
| units on a scale | Vortioxetine |
|---|---|
| Week 12 (n=650) | -2.8 ± 6.69 |
| Week 24 (n=494) | -3.9 ± 6.88 |
| Week 36 (n=414) | -4.0 ± 7.37 |
| Week 52 (n=381) | -4.7 ± 7.11 |
The change between the Sheehan Disability work/school subscale score at each assessed visit and work/school subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.
| units on a scale | Vortioxetine |
|---|---|
| Week 12 (n=650) | -0.8 ± 2.42 |
| Week 24 (n=494) | -1.2 ± 2.48 |
| Week 36 (n=414) | -1.2 ± 2.60 |
| Week 52 (n=381) | -1.4 ± 2.61 |
The change between the Sheehan Disability social life subscale score at each assessed visit and social life subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.
| units on a scale | Vortioxetine |
|---|---|
| Week 12 (n=942) | -1.0 ± 2.53 |
| Week 24 (n=721) | -1.4 ± 2.55 |
| Week 36 (n=617) | -1.4 ± 2.82 |
| Week 52 (n=545) | -1.6 ± 2.85 |
The change between the Sheehan Disability family life/home responsibilities subscale score at each assessed visit and family life/home responsibilities subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.
| units on a scale | Vortioxetine |
|---|---|
| Week 12 (n=942) | -0.9 ± 2.39 |
| Week 24 (n=721) | -1.3 ± 2.47 |
| Week 36 (n=617) | -1.4 ± 2.74 |
| Week 52 (n=545) | -1.6 ± 2.76 |
Collected over 56 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vortioxetine | — | 29/1,073 (2.7%) | 854/1,073 (79.6%) |
| Event | Vortioxetine |
|---|---|
| Suicide attemptPsychiatric disorders | 3/1073 |
| Cholecystitis acuteHepatobiliary disorders | 2/1073 |
| Breast cancer femaleNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/1073 |
| Atrial fibrillationCardiac disorders | 1/1073 |
| Abdominal painGastrointestinal disorders | 1/1073 |
| Esophageal ruptureGastrointestinal disorders | 1/1073 |
| CholecystitisHepatobiliary disorders | 1/1073 |
| CholelithiasisHepatobiliary disorders | 1/1073 |
| Anal abscessInfections and infestations | 1/1073 |
| Latent syphilisInfections and infestations | 1/1073 |
| Event | Vortioxetine |
|---|---|
| NauseaGastrointestinal disorders | 258/1073 |
| HeadacheNervous system disorders | 136/1073 |
| DiarrheaGastrointestinal disorders | 80/1073 |
| VomitingGastrointestinal disorders | 68/1073 |
| NasopharyngitisInfections and infestations | 68/1073 |
| Viral upper respiratory tract infectionInfections and infestations | 66/1073 |
| ConstipationGastrointestinal disorders | 65/1073 |
| Weight increasedInvestigations | 65/1073 |
| Upper respiratory tract infectionInfections and infestations | 60/1073 |
| InsomniaNervous system disorders | 56/1073 |
| Age, Continuous(years) | Vortioxetine |
|---|---|
| Mean | 44.5 ± 12.05 |
| Sex: Female, Male(Participants) | Vortioxetine |
|---|---|
| Female | 790 |
| Male | 285 |
| Race/Ethnicity, Customized(participants) | Vortioxetine |
|---|---|
| Caucasian (or White, including Hispanic) | 813 |
| Black/African American | 249 |
| Asian | 7 |
| American Indian/Alaska Native | 5 |
| Native Hawaiian/Other Pacific Islander | 1 |
| Race/Ethnicity, Customized(participants) | Vortioxetine |
|---|---|
| Hispanic or Latino | 104 |
| Non-Hispanic and Non-Latino | 971 |
| Weight(kg)) | Vortioxetine |
|---|---|
| Mean | 88.77 ± 24.160 |
| Body Mass Index (BMI)(kg/m^2) | Vortioxetine |
|---|---|
| Mean | 31.60 ± 8.061 |
| Height(cm) | Vortioxetine |
|---|---|
| Mean | 167.44 ± 9.456 |
| Montgomery Åsberg Depression Rating Scale (MADRS) total score(scores on a scale) | Vortioxetine |
|---|---|
| Mean | 20.0 ± 10.70 |
2 further baseline measures are reported on the registry.
No study locations are listed for this record.
The record gives a start of Sep 2010, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year after primary completion. A results delay was requested in Oct 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine